S. Hitchcock

发表

Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.

E. Hu, R. Kunz, Shannon Rumfelt, 2012, Bioorganic & medicinal chemistry letters.

From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).

Yuan Cheng, Thomas Nixey, Yi Luo, 2011, Journal of medicinal chemistry.

Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.

S. Hitchcock, Xiaoyang Xia, Yuan Cheng, 2008, Journal of Medicinal Chemistry.

Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease.

Shannon Rumfelt, N. Chen, S. Hitchcock, 2013, Bioorganic & medicinal chemistry letters.

Targeting cannabinoid agonists for inflammatory and neuropathic pain

S. Hitchcock, Yuan Cheng, 2007, Expert opinion on investigational drugs.

Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease.

S. Hitchcock, A. Cheng, Yuan Cheng, 2015, Bioorganic & medicinal chemistry letters.

Synthesis and conformational analysis of a,a-difluoroalkyl heteroaryl ethers

S. Hitchcock, H. Monenschein, Daniel B Horne, 2009 .

Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.

Xiao Mei Zheng, S. Hitchcock, A. Cheng, 2008, Bioorganic & Medicinal Chemistry Letters.

Radiolabeling of a high potency cannabinoid subtype‐1 receptor ligand, N‐(4‐fluoro‐benzyl)‐4‐(3‐(piperidin‐1‐yl)‐indole‐1‐sulfonyl)benzamide (PipISB), with carbon‐11 or fluorine‐18

Sean R. Donohue, S. Hitchcock, C. Halldin, 2008 .

Antifungal patents appearing from June 1995 to June 1997

S. Hitchcock, Michael J. Rodriguez, 1997 .

A tandem radical macrocyclisation-transannular cyclisation approach towards the taxanes

A. J. Blake, S. Hitchcock, A. Blake, 1998 .

A tandem radical macrocyclisation - radical transannulation strategy to the taxane ring system

S. Hitchcock, G. Pattenden, 1992 .

A Remarkable Glycosidation Reaction: The Total Synthesis of Calicheamicin .gamma.1I

S. Hitchcock, M. Chu-Moyer, S. Danishefsky, 1995 .

THE FIRST TOTAL SYNTHESIS OF BACTERIAL CELL WALL PRECURSOR UDP-N-ACETYLMURAMYL-PENTAPEPTIDE (PARK NUCLEOTIDE)

S. Hitchcock, L. Blaszczak, C. Eid, 1998 .

Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.

S. Hitchcock, A. Cheng, R. Fremeau, 2009, Bioorganic & medicinal chemistry letters.

Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists.

S. Hitchcock, L. Arik, V. Viswanadhan, 2008, Bioorganic & medicinal chemistry letters.

Synthesis of macrocycles via allylic radical intermediates. A total synthesis of (−)-zearalenone

S. Hitchcock, G. Pattenden, 1990 .

Structure-brain exposure relationships.

S. Hitchcock, L. Pennington, Lewis D Pennington, 2006, Journal of medicinal chemistry.

Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid.

Yuan Cheng, Wenge Zhong, Michael D Bartberger, 2012, Journal of medicinal chemistry.

Selectivity in palladium(0)-catalyzed cross-coupling reactions: Application to a tandem stille reaction

S. Hitchcock, D. Mayhugh, G. S. Gregory, 1995 .

Structural modifications that alter the P-glycoprotein efflux properties of compounds.

S. Hitchcock, Stephen A Hitchcock, 2012, Journal of medicinal chemistry.

Total synthesis of the mycotoxin (–)-zearalenone based on macrocyclisation using a cinnamyl radical intermediate

S. Hitchcock, G. Pattenden, 1992 .

Total Synthesis of the Mycotoxin (-)-Zearalenone Based on Macrocyclization Using a Cinnamyl Radical Intermediate.

S. Hitchcock, G. Pattenden, 1992 .

Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).

E. Hu, R. Kunz, Shannon Rumfelt, 2012, Bioorganic & medicinal chemistry letters.

Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia

S. Hitchcock, S. A. O. Lim, U. Kang, 2015, Neurobiology of Disease.

An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities.

Xiao Mei Zheng, R. Wahl, S. Hitchcock, 2015, ACS medicinal chemistry letters.

Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's disease.

S. Hitchcock, H. Monenschein, M. Bartberger, 2012, Bioorganic & medicinal chemistry letters.

A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β-Secretase.

Yuan Cheng, Yi Luo, Wenge Zhong, 2012, ACS medicinal chemistry letters.

Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

R. Wahl, S. Hitchcock, Yuan Cheng, 2012, Journal of medicinal chemistry.

Blood-brain barrier permeability considerations for CNS-targeted compound library design.

S. Hitchcock, Stephen A Hitchcock, 2008, Current opinion in chemical biology.

Structure—Brain Exposure Relationships

S. Hitchcock, L. Pennington, 2007 .

A Convergent Total Synthesis of Calicheamicin γI 1.

S. Hitchcock, M. Chu-Moyer, S. Danishefsky, 1994 .

A Convergent Total Synthesis of Calicheamicin γ

S. Hitchcock, M. Chu-Moyer, S. Danishefsky, 1994 .

On the DNA Recognition Role of the Carbohydrate Sector in Calicheamicin: A Comparison of DNA Cleaving Capacity of Enantiomeric Calicheamicinones

D. Crothers, S. Hitchcock, K. Liu, 1994 .

Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist

S. Hitchcock, D. McKinzie, Bin Liu, 2011, Journal of Pharmacology and Experimental Therapeutics.

Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer.

D. Hwang, E. Hu, R. Kunz, 2012, Journal of medicinal chemistry.

Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M₁ agonists.

S. Hitchcock, F. Bymaster, B. Liu, 2015, Bioorganic & medicinal chemistry letters.

Considerations for Target Selection in CNS Drug Discovery Programs

S. Hitchcock, 2012 .

Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activity.

R. Wahl, S. Hitchcock, M. Citron, 2013, Bioorganic & medicinal chemistry letters.

Establishing the Relationship between In Vitro Potency, Pharmacokinetic, and Pharmacodynamic Parameters in a Series of Orally Available, Hydroxyethylamine-Derived β-Secretase Inhibitors

S. Hitchcock, M. Citron, S. Babu-Khan, 2012, Journal of Pharmacology and Experimental Therapeutics.

Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer.

D. Hwang, E. Hu, R. Kunz, 2012, Journal of medicinal chemistry.

Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist

S. Hitchcock, D. McKinzie, Bin Liu, 2011, Journal of Pharmacology and Experimental Therapeutics.